Cathie Wood’s ARK Invest Posts Fund Sales For Thursday, Aug. 12, 2021: OPEN, VEEV, SEER, RHHBY, REGN, PSTI, NVS, NTDOY, TWTR, DOCU, TER, SQ, SHOP, IOVA, SE, MCRB, XONE, GOOG, DDD, BYDDY, TTD, BABA
Opendoor Technologies (OPEN) - 523,533 Shares
Veeva Systems (VEEV) - 26,068
Seer (SEER) - 14,750
Roche (RHHBY) - 132,596
Regeneron Pharmaceuticals (REGN) - 42,669
Pluristem Therapeutics (PSTI) - 92,900
Novartis
Cathie Wood’s ARK Invest Posts Fund Sales For Wednesday, Aug. 11, 2021: TAK, SEER, REGN, PSTI, PSTG, NVS, TWTR, NTDOY, MCRB, DOCU, BIDU, NFLX, GRMN
Takeda Pharmaceutical (TAK) - 189,804
Seer (SEER) - 7,800
Regeneron Pharmaceuticals (REGN) - 13,326
Pluristem Therapeutics (PSTI) - 45,155
Pure Storage (PSTG) - 131,501
Novartis (NVS) - 86,320
Twitter (TWTR) -
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Longeveron’s Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDS
Photo by Anna Shvets from Pexels
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 19)
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Monday
Monday morning, 285 companies reached new 52-week lows.
Cathie Wood’s ARK Invest Posts Fund Sales For Wednesday, July 7, 2021: SE, PSTI, CSTL, CDNA, BMY, TXG, TCEHY, ROKU, PSTG, NVS, IOVA, ICE, BEKE, RAVN, HUYA, LC
Sea (SE) - 54,753 Shares
Pluristem Therapeutics (PSTI) - 1,197
Castle Biosciences (CSTL) - 20,378
CareDx (CDNA) - 7,500
Bristol-Myers Squibb (BMY) - 69,853
10x Genomics (TXG) - 89,450
Tencent (TCEHY) -
Pluristem Says Is Bringing ‘ARDS Associated with COVID-19 Phase II Studies’ To Clinical Readout; Topline Results Expected During Q4
The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and Israel
Topline results are expected during the fourth quarter of